Prognosis for non-small cell lung cancer patients with brain metastases.

Abstract

Brain metastasis has a poor prognosis in patients with advanced non-small cell lung cancer (NSCLC). In this study, we evaluated the prognosis of NSCLC patients with brain metastases. We analyzed a total of 313 NSCLC patients with brain metastasis. We compared the prognoses between a group of less than four (group A) and a group of more than four or equal to four (≥4) (group B) brain metastases. The median survival time was 334 days (group A, 164 patients, 52.4%) and 234 days (group B, 149 patients, 47.6%). Univariate analysis showed that the number of metastases, age at diagnosis of brain metastasis, smoking history, histologic type, and former stage of primary lung cancer before brain metastasis, had a significant influence. In addition, treatment for primary lung cancer lesions and brain metastasis also affected the overall survival (p < .0001). However, there was no difference in the overall survival between the two groups in the multivariate analysis. Our results show that the number of brain metastases, classified by group A (<4) or group B (≥4) did not influence the overall survival of NSCLC patients. However, the overall survival in group A was better than in group B when analyzed, except for local brain treatment modalities in sub-group analysis, suggesting that non-optimized local treatment strategies might cause an unexpected prognosis result in this retrospective study. We suggest that more prospective studies might be needed for the optimal standard treatment for brain metastasis.